Portal de Periódicos da CAPES

Pediatric Contact Dermatitis Registry Inaugural Case Data

2016; Lippincott Williams & Wilkins; Volume: 27; Issue: 5 Linguagem: Inglês

10.1097/der.0000000000000214

2162-5220

Alina Goldenberg, Nico Mousdicas, Nanette B. Silverberg, D. Powell, Janice L. Pelletier, Jonathan I. Silverberg, Jonathan H. Zippin, Luz Fonacier, Antonellá Tosti, Leslie P. Lawley, Mary Wu Chang, Andrew Scheman, Gary Kleiner, Judith V. Williams, Kalman L. Watsky, Cory A. Dunnick, Rachel Frederickson, Catalina Matiz, Keri Chaney, Tracy S. Estes, Nina Botto, Michelle Draper, Leon Kircik, Aída Lugo‐Somolinos, Brian C Machler, Sharon E. Jacob,

Dermatology and Skin Diseases

Little is known about the epidemiology of allergic contact dermatitis (ACD) in US children. More widespread diagnostic confirmation through epicutaneous patch testing is needed.The aim was to quantify patch test results from providers evaluating US children.The study is a retrospective analysis of deidentified patch test results of children aged 18 years or younger, entered by participating providers in the Pediatric Contact Dermatitis Registry, during the first year of data collection (2015-2016).One thousand one hundred forty-two cases from 34 US states, entered by 84 providers, were analyzed. Sixty-five percent of cases had one or more positive patch test (PPT), with 48% of cases having 1 or more relevant positive patch test (RPPT). The most common PPT allergens were nickel (22%), fragrance mix I (11%), cobalt (9.1%), balsam of Peru (8.4%), neomycin (7.2%), propylene glycol (6.8%), cocamidopropyl betaine (6.4%), bacitracin (6.2%), formaldehyde (5.7%), and gold (5.7%).This US database provides multidisciplinary information on pediatric ACD, rates of PPT, and relevant RPPT reactions, validating the high rates of pediatric ACD previously reported in the literature. The registry database is the largest comprehensive collection of US-only pediatric patch test cases on which future research can be built. Continued collaboration between patients, health care providers, manufacturers, and policy makers is needed to decrease the most common allergens in pediatric consumer products.